Sixera Pharma AB
556901-4763ActiveSmall biotech developing first treatment for rare Netherton syndrome.
Biopharmaceutical Companysixerapharma.com
Yleiskatsaus
- 1–4
- Työntekijät
- ≤1t SEK
- Liikevaihto
- 2012
- Perustettu
Kuvaus
Sixera Pharma is a small biopharmaceutical company established in Stockholm in 2013. The company originated from a project spun out of Swedish Orphan Biovitrum (Sobi) and Arexis. Their core mission is to develop their lead compound, SXR1096, into the first available treatment for Netherton syndrome....
Tunnisteet
B2BHealthcarePharmaceuticals
Avainsanat
BiotechnologyDrug DevelopmentNetherton Syndrome
AUTHERA AS